Amundi Sells 20,669 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Amundi cut its Medpace position by 33.8% in the second quarter, selling 20,669 shares and retaining 40,470 shares worth approximately $21.4 million. Institutional investors collectively own 77.98% of the company.
• Medpace reported quarterly EPS of $4.25, beating estimates of $3.98, while revenue rose 17.2% year over year to $707.33 million. The company issued fiscal 2026 EPS guidance of $17.25–$17.95.
• Analysts remain broadly cautious, with three Buy ratings and nine Holds, an average price target of $595.20 versus the stock’s $587.52 price. Insiders have sold 134,471 shares worth about $82.2 million over the past three months.

Amundi lowered its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 33.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 40,470 shares of the company's stock after selling 20,669 shares during the period. Amundi owned about 0.15% of Medpace worth $21,433,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of MEDP. Johnson Financial Group Inc. bought a new position in Medpace in the 2nd quarter worth approximately $27,000. Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Elyxium Wealth LLC purchased a new stake in Medpace in the 4th quarter worth $30,000. Jones Financial Companies Lllp bought a new position in shares of Medpace during the 2nd quarter valued at about $30,000. Finally, Allied Private Wealth LLC bought a new position in shares of Medpace during the 2nd quarter valued at about $31,000. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Price Performance

MEDP opened at $587.52 on Friday. The firm has a market capitalization of $16.40 billion, a PE ratio of 34.44, a price-to-earnings-growth ratio of 2.60 and a beta of 1.15. The business's 50-day moving average is $579.00 and its two-hundred day moving average is $504.67. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts' consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million during the quarter, compared to analysts' expectations of $689.51 million. During the same quarter in the prior year, the company posted $3.10 earnings per share. Medpace's revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Insiders Place Their Bets

In other news, Director Robert Kraft sold 3,858 shares of the business's stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $617.81, for a total transaction of $2,383,510.98. Following the sale, the director owned 955 shares in the company, valued at approximately $590,008.55. The trade was a 80.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Kevin Brady sold 3,400 shares of Medpace stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $625.24, for a total transaction of $2,125,816.00. Following the sale, the chief financial officer owned 12,830 shares of the company's stock, valued at $8,021,829.20. The trade was a 20.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 134,471 shares of company stock worth $82,151,311 in the last three months. Insiders own 20.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on MEDP. BMO Capital Markets raised their price objective on Medpace from $400.00 to $600.00 and gave the company a "market perform" rating in a research report on Friday, July 24th. Truist Financial lifted their price objective on Medpace from $462.00 to $609.00 and gave the stock a "hold" rating in a research note on Friday, July 24th. Royal Bank Of Canada upped their price objective on Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a report on Friday, July 24th. Leerink Partners set a $620.00 target price on Medpace in a research report on Thursday, July 23rd. Finally, Jefferies Financial Group lowered shares of Medpace from a "buy" rating to a "hold" rating and raised their target price for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $595.20.

About Medpace

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.